Johnson & Johnson’s Centocor Ortho Biotech unit said Tuesday it bought RespiVert Ltd., a company developing treatments for asthma and other lung diseases.
Respivert is testing anti-inflammatory drugs that are intended to treat moderate to severe asthma, chronic lung diseases, and cystic fibrosis. The London-based company hopes to start three human clinical trials this year.